The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonot...

The incidence of grade 3 to 4 acute toxicities was similar in patients with high-risk gastric cancer treated with chemoradiation or chemotherapy.

Panelists discuss how to manage borderline transaminase elevations in a patient benefiting from voracidinib therapy, balancing the risk of mild liver...

The rolling submission is supported by data from the PIK3CA wild-type cohort of the phase 3 VIKTORIA-1 trial evaluating gedatolisib in advanced breast...

Panelists discuss current strategies for first-line treatment sequencing in renal cell carcinoma (RCC), emphasizing immunotherapy-based combinations t...

Panelists discuss the shift toward a more personalized approach in metastatic renal cell carcinoma (RCC) management, highlighting the evolving role of...

Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.

The safety profile of sonrotoclax was generally well-tolerated, and emergent toxicities were manageable in patients with mantle cell lymphoma.